Hansson L, Zanchetti A
Department of Geriatrics, Clinical Hypertension Research, University of Uppsala, Sweden.
Blood Press. 1995 May;4(3):133-6. doi: 10.3109/08037059509077584.
The Multicenter Isradipine Diuretic Atherosclerosis (MIDAS) Study was a comparison between the dihydropyridine-derived calcium antagonist isradipine and hydrochlorothiazide in 883 hypertensive patients. B-mode ultrasonography of the carotid artery was used in order to evaluate changes in wall thickness and the development of atherosclerotic plaques during a 3-year period. The final publication has yet to appear in a medical journal. However, the study and its main findings have been presented at several international scientific meetings. In brief, isradipine was significantly more effective than hydrochlorothiazide in preventing an increase in intima-media thickness at several points of measurement in the carotid artery in spite of the fact that systolic blood pressure was not as effectively lowered by isradipine as by the diuretic therapy. Since the results and their implications are of great scientific as well as clinical importance we wish to briefly comment on some of the key aspects of the MIDAS Study, as presented at some international meetings.
多中心异搏定利尿抗动脉粥样硬化（MIDAS）研究对883例高血压患者使用二氢吡啶类钙拮抗剂异搏定和氢氯噻嗪进行了比较。为评估3年期间颈动脉壁厚度的变化和动脉粥样硬化斑块的发展情况，采用了B型超声检查。最终的研究报告尚未发表在医学期刊上。不过，该研究及其主要发现已在多个国际科学会议上进行了展示。简而言之，尽管异搏定降低收缩压的效果不如利尿剂治疗，但在颈动脉多个测量点预防内膜中层厚度增加方面，异搏定比氢氯噻嗪显著更有效。鉴于这些结果及其意义具有重大的科学和临床重要性，我们希望就MIDAS研究在一些国际会议上展示的一些关键方面进行简要评论。
